Naturally occurring drug resistance genes of human origin can be exploited for selection of genetically engineered cells co-expressing a desired therapeutic transgene. Their nonimmunogenicity in clinical applications would be a major asset. Human cytidine deaminase (hCD) is a chemoresistance gene that inactivates cytotoxic cytosine nucleoside analogs, such as cytosine arabinoside (Ara-C). The aim of this study was to establish if the hCD gene can serve as an ex vivo dominant selectable marker in engineered bone marrow stromal cells (MSCs). A bicistronic retrovector comprising the hCD cDNA and the green fluorescent protein (GFP) reporter gene was generated and used for transduc
Introduction
Transgene expression in a plurality of engineered target cells is an essential but challenging goal in many cell and gene therapy applications. One approach to achieve this would be to dominantly select and enrich ex vivo the cells concomitantly expressing a therapeutic transgene and a linked dominant selectable marker gene. Numerous investigators have employed dominant selection strategies utilizing drug resistance genes, such as the prokaryotic neomycin phosphotransferase II (Neo R ) gene, 1,2 the human multidrug resistance (MDR) gene, [3] [4] [5] the mutated human dihydrofolate reductase (DHFR) genes, 6, 7 and the human O 6 -methylguanine-DNA-methyltransferase (MGMT) gene. 8, 9 However, disadvantages have been noted with some drug selectable markers. For instance, cells modified with the prokaryotic Neo R gene may elicit an immune reaction in vivo, 10 MDR-transduced hemato- poietic stem cells, when transplanted in mice, can lead to a myeloproliferative syndrome, 5 and MGMT gene-modified cells require selection with the DNA damaging alkylating agents. 11 Desirable features for a drug selectable marker would include low or absent immunogenicity, little or no collateral biochemical perturbation of engineered cells and lastly, chemical selection with drugs having low mutagenic activity.
In previous studies, we cloned and expressed the human cytidine deaminase cDNA which consists of 910 bp encoding an 146 amino acid protein of 16.2 kDa. 12 Human cytidine deaminase (hCD) (EC 3.5.4.5) is an enzyme that catalyzes the deamination of cytidine or deoxycytidine to uridine or deoxyuridine, respectively. 13 It is normally expressed in a wide array of normal cells and tissues, especially liver and spleen. Increased expression of the endogenous hCD gene in malignant cells has been linked to chemotherapy resistant leukemias in humans. This observation led to the study of the hCD gene in chemoprotective gene therapy. Indeed, we have shown that the hCD drug resistance gene has promise for protecting normal hematopoietic cells from the doselimiting myelotoxicity of anti-cancer drugs cytosine nucleoside analogs, such as cytosine arabinoside (Ara-C).
14, 15 Furthermore, we determined in mice transplanted with hCD gene-modified hematopoietic cells, hCD proviral DNA persistence and long-term expression in various tissues. 16 In contradistinction, E. coli cytosine deaminase, a gene related to hCD, but with different substrate specificity, has been widely investigated as a 'suicide' gene due to its unique ability to convert the prodrug 5-fluorocytosine (5FC) to its cytotoxic metabolite 5-fluorouridine (5FU). 17 It must be noted that human cytidine deaminase enzyme is distinct from E. coli cytosine deaminase, and there is only 28% homology between the two proteins. Furthermore, hCD is incapable of converting 5-FC to 5-FU. However, hCD can deaminate synthetic cytotoxic cytosine nucleoside analogs such as Ara-C, causing their pharmacologic inactivation. 18, 19 Human CD possesses several important assets as a dominant selectable marker for ex vivo clinical use in humans. It is a non-allelic, non-mutated protein of human origin. Therefore, in theory, immune recognition and rejection of hCD-expressing cells, as has been described with non-mammalian genetic markers such as neomycin phosphotransferase II and green fluorescent protein, 10 should not occur in immunocompetent humans. 20, 21 hCD can be best described as a 'housekeeping' enzyme, whose overexpression is unlikely to transform engineered cells into an undesirable phenotype, malignant or otherwise. Moreover, hCD efficiently confers resistance to Ara-C, a drug with low mutagenic potential, widely used clinically for the therapy of acute leukaemia. 22, 23 The sum of these features identifies hCD as a highly desirable dominant selectable marker in transgenic cell therapy applications.
Several investigators have revealed the utility of bone marrow-derived stromal cells (MSCs) as pluripotent stem cells. [24] [25] [26] [27] These cells in their native 'pluripotent' state can be used in an allogeneic cell therapy transplant setting in humans with mesenchymal disorders. 28 Furthermore, autologous MSCs and their 'differentiated' output could be genetically engineered for additive therapeutic effect in cell and gene therapy strategies in a wide assortment of ailments. These autologous cells, which are easily isolated from bone marrow aspirates, expanded in culture, and gene modified, have also been genetically engineered for the expression of an exogenous gene product and/or for the secretion of therapeutic proteins in vitro and in vivo. [29] [30] [31] [32] Dominant selection of gene-modified MSCs ex vivo would allow a greater proportion of cells to express therapeutically relevant levels of the beneficial gene product in vivo thus enhancing clinical effectiveness.
We propose that the hCD cDNA may serve as a useful and safe ex vivo positive selectable marker with cytosine nucleoside analogs in genetically engineered primary autologous stromal cells for use in transgenic cell therapy applications. In the present study, we designed a bicistronic integrating retrovector expressing the hCD cDNA and the GFP reporter, transduced primary murine MSCs and tested whether in vitro dose-dependent selection and enrichment of hCD gene-modified stromal cells using Ara-C was feasible and if these cells retained progenitorlike features when implanted in syngeneic animals. 
Results

Retrovector transfer and expression in A549 human carcinoma cell line
In order to demonstrate that the recombinant retroviral construct CD-IRES-EGFP ( Figure 1 ) did not undergo any rearrangements or deletions before integration as proviral DNA into the genome of transduced cells, Southern blot analysis was carried out on gene-modified A549 cells. A DNA band corresponding to the 3683 bp fragment expected from NheI digest of integrated unrearranged CD-IRES-EGFP proviral DNA (Figure 2 ) was revealed. In A549-CD-IRES-EGFP cells selected with 2.5M Ara-C, the DNA band detected was of higher intensity than that of cells exposed to 1 M Ara-C, and notably more so than that of CD-transduced cells which were not drug selected ( Figure 2) . To evaluate the CD activity in genetically engineered cells, enzyme assay was performed on the cytosolic extract of A549 cells transduced with CD-IRES-EGFP retroviral particles and on that of control cells, ie untransduced A549 cells, as well as A549 cells modified with IRES-EGFP virions. At an MOI of approximately 10, >90% of A549 cells were transduced, as documented by GFP reporter expression (data not shown). No Ara-C selection was performed on this mixed population and CD activity was assessed. As detailed in Table 1 , parental A549 cells as well as A549- IRES-EGFP cells showed low CD activity, specifically 0.29 ± 0.07 and 0.53 ± 0.07 units/mg of total protein, respectively. In contrast, the CD activity of A549-CD-IRES-EGFP cells was 515 ± 31 units/mg of total protein, representing an approximate 1000-fold augmentation (P Ͻ 0.0001).
CD retrovector expression and acquired resistance to cytosine nucleoside analogs
The sensitivity of genetically engineered A549 cells to the toxicity of cytosine nucleoside analogs Ara-C and dFdC was evaluated by MTT assay. As depicted in Figure 3a , the concentration of Ara-C that inhibits cell proliferation by 50%, IC 50 , was 9.5-fold greater for A549-CD-IRES-EGFP cells (IC 50 : 0.87 M) as compared with A549-IRES-EGFP cells (IC 50 : 0.09 M) (P Ͻ 0.001). To ascertain that these hCD gene-modified human cells are not resistant uniquely to Ara-C, but have conjointly acquired crossresistance to other cytosine nucleoside analogs, growth suppression by dFdC was also evaluated. As shown in Figure 3b , the dFdC concentration that suppressed cell growth by 50% for A549-CD-IRES-EGFP cells (IC 50 : 0.34 M) was over 10-fold greater than for A549-IRES-EGFP cells (IC 50 : 0.03 M) (P Ͻ 0.001).
Ex vivo selection and enrichment of hCD gene-modified primary mouse marrow stromal cells
Flow cytometry analysis for GFP reporter expression was performed on primary mouse MSCs 72 h following their transduction with amphotropic retroparticles as described in Materials and methods. The percentage of green fluorescent cells was 98% for stroma engineered with CD-IRES-EGFP retroparticles and 96% for cells modified with Neo R -IRES-EGFP virus, as compared with 2.1% for untransduced MSCs. To determine if in vitro selection of hCD-expressing stroma can occur, CD-IRES-EGFP transduced MSCs were mixed at 10, 20, 30 and 100% proportions with untransduced stroma, cultured in 2.5 M Ara-C for 7 days, and expanded for 1 additional week. Consequently, flow cytometry analysis for GFP reporter expression revealed, as indicated in Figure 4 , selective expansion of GFP expressing cells to >99.5% for all cell combinations exposed to Ara-C. This Ara-C concentration of 2.5 M was noted to completely eradicate untransduced, as well as Neo
R -IRES-EGFP-modified
Figure 4 In vitro selection of CD-IRES-EGFP transduced primary mouse marrow stromal cells. Primary mouse marrow stromal cells were genetically engineered with CD-IRES-EGFP retrovirions and mixed with untransduced cells so as to constitute approximately 10, 20, 30 and 100% of the cell population. Each combination of cells was then cultured in the absence (a-d) and presence (a'-d') of 2.5 M Ara-C for 7 days and expanded for an additional week. Percentage GFP-positive cells was assessed by flow cytometry analysis. Experiment repeated two further times and similar results obtained. GFP acts as a reporter of retrovector expression in gene-modified cells. The percentage of GFP-positive cells is indicated in the upper right of panel.
stroma. We also tested whether in vitro selection and enrichment of hCD gene-modified marrow stroma is dose-dependent. A cell mixture consisting of 10% CD-IRES-EGFP vector-bearing MSCs and 90% untransduced MSCs was exposed to increasing concentrations of Ara-C for 1 week and subsequently cultured for another week. Flow cytometry analysis revealed that the degree of selective expansion of the GFP-positive cells was dependent on the dose of Ara-C ( Figure 5 ). As illustrated in Figure 5a , in a mixture containing 10% CD-IRES-EGFP transduced MSCs and 90% untransduced MSCs, the GFP+ cells increased to 51, 80 and >99.5% following in vitro drug selection with 0.25, 0.5, and 1 M Ara-C, respectively. Drug dose had a very obvious impact on the level of transgene expression, as measured by the mean green fluorescence intensity (MFI) rising from 13.0 ± 3.0 in the absence of Ara-C to 48.3 ± 6.5 and 99.3 ± 3.3
Gene Therapy in cells selected with 1 and 2.5 M Ara-C, respectively ( Figure 5b ). To evaluate the CD activity in genetically engineered in vitro selected murine marrow stroma, enzyme assay was performed on the cytosolic extract of a mixture containing 10% CD-IRES-EGFP gene-modified MSCs and 90% untransduced MSCs following drug selection with various concentrations of Ara-C. As illustrated in Figure 5c , CD activity rose from 234 ± 17.0 units/mg of protein in the absence of Ara-C, to 838 ± 66.1, 1139 ± 36.2 and 1296 ± 9.78 units/mg of total protein, following exposure to 0.25, 0.5 and 1 M Ara-C, respectively. In addition, drug selection with 2.5 M Ara-C resulted in a CD activity level of 1529 ± 160 units/mg of protein, representing an approximate 6.5-fold increase as compared with the unselected cell population (Figure 5c ). Untransduced marrow stromal cells demonstrated low CD activity, 0.65 ± 0.35 units/mg of protein, whereas the CD activity in a population of 100% CD-IRES-EGFP genemodified cells was 1239 ± 36.0 units/mg of protein, indicating an over 1900-fold augmentation (data not shown). The growth rate of CD-IRES-EGFP vector-bearing stromal cells was identical in drug-free and 2.5 M Ara-C containing media and their cytological phenotype as assessed by microscopic examination remained unchanged (data not shown).
In vivo engraftment and differentiation of ex vivo drug selected gene-modified stroma
To determine that ex vivo drug selection of hCD engineered stroma does not alter in vivo engraftment and differentiation capacity, 10% CD-IRES-EGFP-positive mouse stroma enriched to >99% by Ara-C exposure was thereafter gene-modified to also express ␤-galactosidase, embedded in Matrigel, and implanted by subcutaneous injection in non-myeloablated, immunocompetent syngeneic C57Bl/6 mice. Sections of the implant harvested 4 weeks later showed engrafted, ex vivo drug-selected, transgene-expressing cells. Based on LacZ gene reporter activity, we detected the Ara-C-selected marrow stromal cells randomly dispersed within the implant with a fibroblast-like histological appearance but also, as shown in Figure 6 , incorporated in the wall of blood vessels. These cells had taken the histological configuration of endothelial cells and had become CD31 + ( Figure 6 ). These observations are compatible with the in vivo phenotypic differentiation of MSCs into endothelium.
Discussion
Retroviral gene transfer permits stable integration of a foreign gene in the chromosomal DNA of the host cell and all progeny cells, and remains the preferred means of engineering cells with a high proliferation rate subsequent to gene transfer, such as progenitor and stem cells. 33 Cell and gene therapy of many hereditary and acquired illnesses requires that the desired therapeutic gene be efficiently expressed and translated in the majority of engineered cells before their in vivo use. Though integrating gene transfer vehicles vary in their transduction efficiency, limitations dictated by target cell variables often leads to suboptimal gene transfer efficiency when targeting a mixed population of primary cells. 34, 35 One possible means to overcome this obstacle would be to expand the proportion of gene-modified cells in vitro through dominant selection relying on the co-Gene Therapy
Figure 5 Dose-dependent selection and enrichment of CD-IRES-EGFP gene-modified primary mouse marrow stromal cells. Primary mouse marrow stromal cells were transduced with CD-IRES-EGFP retroviral particles and mixed with untransduced cells so as to comprise about 10% of the total population. Cells were then cultured in the presence of various concentrations of Ara-C for 7 days and expanded for an additional week. Flow cytometry analysis was conducted to determine percentage of GFP-positive cells and mean fluorescence intensity of GFP-expressing cells. CD enzyme assay was performed on the cytosolic extracts to ascertain CD activity in these cells. (a) Flow cytometry analysis of one representative experiment demonstrating dose-dependent selective expansion of CD-IRES-EGFP-transduced stromal cells. The percentage of GFP-positive cells is indicated in the center right of the panel. (b) Mean fluorescence intensity of GFP-expressing marrow stromal cells is plotted against Ara-C concentration. Average ± s.e.m. (n = 3). (c) CD enzyme activity of Ara-C exposed CD-IRES-EGFP transduced stroma is plotted against Ara-C concentration. Average ± s.e.m. (n = 3-6).
expression of a drug resistance gene. The objective of the current report was to determine if the human drug resistance gene cytidine deaminase (hCD) can serve as an ex vivo positive selectable marker in genetically engineered primary autologous cells.
To test this hypothesis, we generated a bicistronic retroviral vector enclosing the hCD cDNA and the GFP reporter gene, where GFP represents a non-selectable therapeutic gene. We showed that the CD-IRES-EGFP retrovector was integrated as an intact proviral DNA in the genome of transduced cells, since no rearrangements nor deletions were revealed by Southern blot analysis of gene-modified cells (Figure 2 ). Functional hCD expression in CD-IRES-EGFP vector-bearing A549 cells was increased by 1000-fold following stable transduction (Table 1) , leading to acquired resistance to cytosine nucleoside analogs Ara-C and dFdC (Figure 3) .
In this present study, we also demonstrated efficient in vitro drug selection of gene-modified primary murine MSCs. Mouse MSCs transduced with CD-IRES-EGFP retroparticles and subsequently combined with untransduced stroma so as to constitute 10, 20, 30 and 100% of total cells were in all cases enriched with 2.5 M Ara-C treatment to >99% gene-modified populations, as assessed by flow cytometry analysis for the linked GFP expression (Figure 4) . We established that the selective in vitro expansion of transgene expressing cells was drug dose-dependent, as observed by exposing the 10% CD-IRES-EGFP-containing stromal cells to a range of Ara-C concentrations ( Figure 5 ). We have noted not only the dose-dependent enrichment of the retrovector-positive MSCs, but also the dose-dependent enrichment of the cells possessing the strongest levels of transgene expression. Accordingly, as illustrated in Figure 5b and c, Ara-C dose escalation for in vitro selection of geneGene Therapy modified stromal cells brought about retrovector expression augmentation, as shown by an approximate six-fold increase in both the mean fluorescence intensity (MFI) and the CD enzyme activity. These findings indicate that Ara-C treatment of cells following transduction serves not only to eradicate the non-altered cells, but also the low hCD-expressors, thus enriching the proportion of cells with high linked-reporter expression. Amplification of the hCD proviral DNA may have also occurred with intensive Ara-C treatment of CD-IRES-EGFP transduced MSCs. The stronger retrovector signal detected with hCD gene-modified A549 cells selected with 2.5 M Ara-C versus that with l M Ara-C-treated cells, or the weakest band seen with unselected cells (Figure 2) , indicates an augmented copy number of the proviral sequences. This higher copy number suggests selection and enrichment of the hCD positive cells with multiple integrants and/or amplification of the hCD gene by Ara-C exposure of genetically engineered cells. In a previous investigation, we discovered that it was possible to increase, with Ara-C exposure of hCD-transduced fibroblast cells, hCD expression via amplification of the proviral hCD gene. 36 Characteristics of an optimal drug resistance gene as a potential positive selectable marker comprise its effectiveness at imparting significant drug resistance, its small cDNA not imposing size constraints on the therapeutic gene included in the bicistronic vector, and most importantly its inability to raise an immune response. Numerous investigations have reported the use of drug resistance genes for in vivo selection of genetically altered cells. 37, 38 The disadvantages of in vivo drug selection, such as the systemic side-effects of chemotherapeutic agent administration, are not encountered with in vitro drug selection, since enrichment of the population of strong transgene-expressing cells is conducted before transplantation/implantation. Gene transfer studies regularly employ drug resistance genes for the in vitro selection of genetically engineered cells. For instance, the neomycin phosphotransferase II (Neo R ) drug resistance gene confers to transduced cells the ability to be selectively expanded through treatment with neomycin or its analog G4l8.
1,2 The Neo R gene, however, is not a suitable selectable marker for clinical applications since it is prokaryotic and immunogenic. 10 Moreover, one study reported the adverse effect of the Neo R gene on the concomitant expression of a second gene product. 39 Therefore, retroviral transfer of a selectable drug resistance gene may in some cases confer lower expression of the therapeutic transgene or raise an immune reaction against gene-modified cells, ultimately reducing the effectiveness of the gene therapy approach. 40 The immunogenicity of certain drug selectable genes such as Neo R , led to their removal in later studies. 10, 41 In contrast to selectable markers of prokaryotic origin, 10,42 the hCD gene since it is of human origin is not anticipated to be immunogenic in clinical applications, and as we demonstrated in the current study, has not impeded but enhanced the expression of a second transgene from a bicistronic retrovector.
Another selectable gene, the human multidrug resistance gene (MDR) which codes for the multidrug transporter P-glycoprotein has been described and utilized as a dominant selectable marker with MDR-responsive chemotherapeutic agents, such as paclitaxel and colchicine.
3-5 Nonetheless, some investigators observed a mye-loproliferative syndrome in mice transplanted with MDR-transduced hematopoietic stem cells. 5 The drug resistance gene O 6 -methylguanine-DNA-methyltransferase (MGMT) codes for a DNA repair enzyme that when overexpressed renders normal mammalian cells resistant to O 6 -alkylating agents, such as the nitrosoureas and related methylating compounds. 8, 9, 43 However, since these antineoplastic drugs produce DNA damage which may have toxic or mutagenic repercussions, 11 their use for dominant selection of gene-modified cells may be hazardous. Alternative dominant selectable markers that are well-defined and widely utilized comprise the mutant variants of the human dihydrofolate reductase (DHFR) gene which maintain a role in folate metabolism when introduced into cells, but confer drug resistance against the cytotoxicity of antifolates, such as methotrexate and trimetrexate. 44, 45 Several investigators have successfully accomplished in vitro drug selection of mutant DHFRtransduced cells, 7 including MSCs. 6, 7 However, despite selection in saturating concentrations of antifolate drug in vitro, up to 20% of primary untransduced MSCs will survive, thereby somewhat limiting the ability to remove contaminating, non-engineered cells. Like DHFR, CD confers resistance to non-mutagenic cytotoxic drugs, a desirable feature in regard to clinical use. Therefore, it is a further advantage of the hCD gene as a positive selectable marker that the drugs required for ex vivo selection, cytosine nucleoside analogs, are antimetabolites that are unlikely to cause DNA damage in hCD-enriched cells. Further, unlike antifolates, Ara-C will readily eradicate untransduced MSCs in vitro, and allow for selection of engineered cells to virtual purity.
Human CD also distinguishes itself from fluorescent or membrane-bound reporter proteins by the absence of immunogenicity 20 and unlikelihood of pseudotransduction. 46 Our findings suggest that the introduction of the hCD dominant selectable marker in MSCs would allow selection and enrichment of genetically engineered cells ex vivo. MSCs possess many attractive characteristics for use in therapeutic applications. These cells are found in sufficient amount in humans of all ages; they can be harvested with little discomfort by bone marrow aspiration without prior mobilization treatment; they can be easily culture-expanded and gene-modified; and have the ability to engraft when reintroduced into the donor without the requirement for toxic conditioning regimens. 24, 27, 47 Bone marrow stromal cells have the ability to differentiate into various cell types, including chondrocytes, osteoblasts, adipocytes, myoblasts, cardiomyocytes, astrocytes, fibroblasts, skeletal myoblasts, tenocytes and smooth muscle cells. [24] [25] [26] [27] 48 Therefore, due to their capacity for self-renewal and differentiation and to the retention of their precursor phenotype subsequent to genetic engineering and culture expansion, MSCs are an ideal target for cell and gene therapy approaches, such as for the treatment of osteogenesis imperfecta 24, 28 and for cellular cardiomyoplasty. 49 The use of differentiated stroma for tissue and organ repair will likely be enhanced if these same cells are engineered in a manner improving their utility. Possible strategies, as we and others have shown, may include the use of MSCs for the expression of an exogenous gene product, and as an efficient autologous cellular vehicle for the secretion of beneficial proteins in vitro and in vivo. 24 50 Conceivably, hCD may be utilized as a positive selectable marker for the therapy of autoimmune diseases such as arthritis or multiple sclerosis, by selectively enhancing cells genetically engineered to express anti-inflammatory gene products. 51 Moreover, gene transfer of hCD for ex vivo selection may potentially be used to augment the proportion of differentiated stromal cells gene-modified for the neoangiogenic cellular treatment of cardiovascular or cerebral ischemia. 49 MSCs have been shown to have mesenchymal progenitor features, including the ability to differentiate into CD31
+ endothelial cells in vitro. 52 These progenitor-like features may be exploited for tissue and organ repair functions. 52, 53 In the present study, we noted that ex vivo drug selection of hCD gene-modified primary marrow stroma does not alter its capability to subsequently engraft, and maintain its mesenchymal progenitor cell potential in vivo ( Figure  6 ). Indeed, implanted marrow stromal cells acquired a histology and immunophenotype coherent with endothelial cells, as noted by up-regulation of CD31 marker (culture expanded MSCs are CD31 null) and by their occurrence near and within vascular structures in vivo.
In conclusion, our results reveal the potential of the human cytidine deaminase gene for the ex vivo selective enrichment of genetically engineered primary marrow stromal cells for cell and gene therapy purposes. Future studies will test the effectiveness of this positive selectable marker when linked to therapeutic synthetic nucleic acid sequences for treatment of hereditary and acquired illnesses.
Materials and methods
Cell lines GP+E86 ecotropic and GP+envAM12 amphotropic retrovirus packaging cell lines, kindly supplied by A Bank (Columbia University, New York, NY, USA), 54, 55 were maintained in DulbeccoЈs modified Eagle medium (DMEM) (Canadian Life Technologies, Burlington, Ontario, Canada) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Wisent Technologies, St Bruno, Quebec, Canada) and 5 g/ml gentamicin (Canadian Life Technologies). The 293GPG retrovirus-packaging cell line, generously provided by RC Mulligan (Children's Hospital, Boston, MA, USA), 56 was grown in 293GPG media (DMEM supplemented with 10% heat-inactivated FBS, 300 g/ml G418 (Mediatech, Herndon, VA, USA), 2 g/ml puromycin (Sigma, Oakville, Ontario, Canada), 1 g/ml tetracycline (Fisher Scientific, Nepean, Ontario, Canada), and 50 U/ml penicillin/streptomycin (Pen/Strep) (Wisent)). A549 human lung carcinoma cells, obtained from American Type Culture Collection (ATCC), were maintained in RPMI 1640 medium (Canadian Life Technologies) supplemented with 10% heat-inactivated FBS. NIH 3T3 mouse fibroblast cells, from ATCC, were cultured in DMEM with 10% FBS and 50 U/ml Pen/Strep. All cells were grown in a humidified incubator with 5% CO 2 .
Retroviral vector design and virus-producing cell line generation
The murine stem cell virus (MSCV)-derived retroviral vector pIRES-EGFP, a bicistronic construct comprising a multiple cloning site linked by an internal ribosomal entry site (IRES), to the enhanced green fluorescent protein (EGFP) reporter, was synthesized as previously reported. 57 The retroviral vector pCD-IRES-EGFP ( Figure  1 ) was synthesized by retrieving the human cytidine deaminase (CD) cDNA sequence by NcoI/Klenow and BamHI digest of the pMFG-CD construct previously described, 58 and ligating it with a XhoI/Klenow and BamHI digest of pIRES-EGFP. The retrovector pNeo R -IRES-EGFP, encompassing the neomycin phosphotransferase II drug resistance gene, was similarly constructed.
The pCD-IRES-EGFP vector (10 g) was introduced into GP+E86 packaging cells by calcium phosphate transfection utilizing the Cell Phect kit (Amersham Pharmacia Biotech, Baie d'Urfé, Quebec, Canada) and cells were subsequently selected for 3 weeks in complete medium supplemented with 2.5 M cytosine arabinoside (Ara-C) (Upjohn, Don Mills, Ontario, Canada). The ensuing stable polyclonal producer cell population was used to supply virus for the transinfection of GP+envAM12 amphotropic packaging cells. Briefly, for 3 consecutive days, retrovirus-containing supernatant was harvested from subconfluent ecotropic producer cells, filtered with a 0.45-m syringe mounted filter (Gelman Sciences, Ann Arbour, MI, USA) and applied with 8 g/ml Polybrene (Sigma, St Louis, MO, USA) over target GP+envAM12 cells. A polyclonal population GP+envAM12-CD-IRES-EGFP was drug selected by culturing in media including 2.5 M Ara-C. As a control, the GP+envAM12-Neo R -IRES-EGFP polyclonal producer was generated in an almost identical manner to that described above, the exception being that drug selection was performed with 400 g/ml G418-containing media. Vesicular stomatitis virus G-protein (VSV-G) pseudotyped retroparticles were also generated with the use of pantropic 293GPG packaging cell line as previously described. 57 In brief, 293GPG packaging cells were co-transfected with 5 g pCD-IRES-EGFP and 70 ng pJ6⍀Bleo 59 and then were selected in 293GPG media supplemented with 100 g/ml Zeocin (Invitrogen, San Diego, CA, USA) consequently generating the stable polyclonal producer 293GPG-CD-IRES-EGFP. By this same approach, the control 293GPG-IRES-EGFP producer was also generated. Retroparticles from virus producers were noted to be free from replication competent retrovirus (RCR) by GFP marker rescue assay employing supernatant from transduced target cells. In addition, GP+E86-LacZ cells were generated by transinfection of the GP+E86 cell line with filtered retroviral supernatant from the 293GPG-LacZ producer (kindly provided by RC Mulligan, Children's Hospital, MA, Gene Therapy USA) twice a day for 3 consecutive days, in the presence of 6 g/ml lipofectamine.
Titration of retrovirus producers
To determine the titer of GP+E86 and GP+envAM12 producers, NIH 3T3 cells were utilized, whereas A549 cells were used for titering 293GPG producers. These target cells were plated at a density of 2 to 4 × 10 4 cells per well of six-well tissue culture dishes and the following day, cells from one test well were trypsinized and counted to ascertain the baseline cell number at the time of virus addition. For transduction, serial dilutions of 0.45 m filtered retroviral supernatants (0.01 to 100 l in a final volume of 1 ml complete media), supplemented with 8 g/ml polybrene, were placed over the adherent target cells. Flow cytometry analysis was realized 72 h after transduction to measure the percentage of GFP-expressing cells. 
Transduction of human A549 cells and analysis
Retroviral supernatant was collected from 293GPG-CD-IRES-EGFP cells grown to confluence in 293GPG media devoid of tetracycline for over 72 h. Media containing VSVG-pseudotyped retroparticles was 0.45 m filtered, supplemented with 8 g/ml polybrene and overlaid on subconfluent A549 cells for a multiplicity of infection (MOI) of approximately 10 infectious particles per target cell. This transduction procedure was repeated daily for 3 consecutive days, yielding A549-CD-IRES-EGFP cells. As a control, A549 cells were likewise transduced with retroviral particles from 293GPG-IRES-EGFP producers, hence giving rise to A549-IRES-EGFP cells. Five days following the last transduction round, flow cytometry analysis was performed to determine gene transfer efficiency and GFP reporter expression. Green fluorescence was 96% for A549-CD-IRES-EGFP cells and 92% for A549-IRES-EGFP cells, in contrast to Ͻ0.5% for untransduced control A549 cells. No Ara-C drug selection was required for generation or maintenance of these mixed populations, unless otherwise specified.
Southern blot analysis
Genomic DNA was isolated from CD-IRES-EGFP stably transduced A549 cells untreated or selected in 1 M or 2.5 M Ara-C, as well as from control cells, using the QIAamp DNA mini kit (Qiagen, Mississauga, Ontario, Canada). For Southern blot analysis, 5 g of genomic DNA was digested with NheI and separated by agarose gel electrophoresis. Following UV photography with a fluorescent ruler, the gel was immersed in denaturing solution (0.5 M NaOH; 1.5 M NaCl) and then in neutraliz-ing buffer (0.5 M Tris-HCl pH 7; 1.5 M NaCl, pH 7), each for 45 min. The DNA in the gel was transferred on to a Hybond-N nylon membrane (Amersham, Oakville, Ontario, Canada) using 10× standard saline sitrate (SSC) for an approximately 48-h downward transfer with the Turbo Blotter device (Schleicher and Schuell, Keene, NH, USA). The membrane was then UV-irradiated in a Bioslink UV linker with 0.3 J/cm 2 , hydridized in Express Hyb solution (Clontech, Palo Alto, CA, USA) containing PCR-amplified 32 P-labeled cDNA for hCD, and washed. The membrane was subsequently exposed to phosphor screens and results visualized using a Phosphor Imager. 
Growth inhibition assay of gene-modified A549 cells
Harvest, expansion and transduction of primary mouse bone marrow stroma
One female C57Bl/6 mouse was killed by CO 2 inhalation, and bone marrow cells harvested by flushing the femurs and tibias with DMEM supplemented with 10% FBS and 50 U/ml Pen/Strep. Whole marrow was plated in 10 cm tissue culture dishes and 5 days later, the nonadherent hematopoietic cells were discarded and the adherent MSCs cultured (for approximately 3 months) at 37°C with 5% CO 2 . Supernatant (0.45 m filtered) containing infectious retroparticles from subconfluent GP+envAM12-CD-IRES-EGFP or from control GP+envAM12-Neo R -IRES-EGFP producers was placed over MSCs plated at approximately 60% confluency for an MOI of approximately 10 infectious particles per target cell. Transduction was carried out twice a day for 3 successive days in the presence of 6 g/ml lipofectamine. Over 72 h following the last transduction round, flow cytometry analysis for GFP expression was performed to evaluate the gene transfer efficiency.
In vitro selection and enrichment assay of hCD genemodified marrow stroma CD-IRES-EGFP transduced stromal cells were mixed in various proportions (10, 20, 30 and 100%) with untransduced stromal cells, and plated at a density of 25 000 cells/well of six-well plates with Ara-C at a final concentration of 2.5 M. Drug exposure was ceased 7 days later, and cells expanded for an additional week in DMEM with 10% FBS and 50 U/ml Pen/Strep and analyzed by flow cytometry analysis. Moreover, the cell combination where CD-IRES-EGFP modified stroma constituted 10% of total cell number was plated at 25 000 cells/well of six-well dishes with a range of Ara-C concentrations (0.25 to 2.5 M) for 7 days. These cells were subsequently expanded in Ara-C-free medium for another 7 days. Cells were trypsinized and percentage GFP-positive cells and mean GFP fluorescence were evaluated by flow cytometry analysis.
CD enzyme assay
Stably transduced test and control A549 cells, as well as CD-IRES-EGFP gene-modified mouse marrow stromal cells mixed with untransduced stroma and selected in various concentrations of Ara-C were assayed for CD enzyme activity as previously described. 60 Adherent cells (2-5 × 10 7 cells) were trypsinized, washed with phosphate-buffered saline (PBS) and resuspended in 5 mM Tris-HCl (pH 7.4) and 5 mM dithiothreitol. The cell suspension was freeze-thawed rapidly three times, centrifuged at high speed (12 000 r.p.m.) for 15 min and the supernatant consisting of the cytosolic extract was collected. For CD enzyme assay, various dilutions of the cytosol were utilized in a reaction mixture with 50 mM Tris-HCl and 0.5 Ci H-cytidine (ICN Biomedicals, Irvine, CA, USA). The reaction was allowed to proceed for 30 min at 37°C and then stopped with cold HCl (0.001 N). The mixture was subsequently poured on to Whatman P-81 phosphocellulose discs (Clifton, NJ, USA) and the quantity of radioactivity bound to the discs determined by scintillation counting. Only cytosine nucleosides, and not the deaminated uracil nucleosides, are bound to the discs. One unit of enzyme activity was defined as the amount of enzyme that catalyzes the deamination of 1 nmol of 3 H-cytidine per min at 37°C. Total protein concentration was determined using the BioRad protein assay (BioRad Laboratories, Mississauga, Ontario, Canada) with bovine serum albumin as the standard.
LacZ-transduction and subcutaneous implantation of ex vivo-selected hCD gene-modified marrow stroma
The 10% CD-IRES-EGFP positive marrow stromal cell mixture expanded to over 99% by ex vivo drug selection with 2.5 M Ara-C was thereafter engineered to express ␤-galactosidase by transduction with retroparticles from GP+E86-LacZ producers. Transduction was accomplished twice per day for 3 consecutive days with 6 g/ml lipofectamine and resulting cells expanded for approximately 2 weeks. 4 × 10 6 cells in 50 l volume RPMI medium were mixed with 500 l Matrigel (Becton Dickinson, Franklin Lakes, NJ, USA) at 4°C and implanted by subcutaneous injection in the right flank of syngeneic C57Bl/6 mice. Matrigel, at body temperature, rapidly acquires a semi-solid form and thus was utilized here as a three-dimensional in vivo model of marrow stroma differentiation.
Matrigel implant recovery and processing
At 4 weeks after implantation, mice were killed and their systemic circulation flushed through the left ventricle with 15 ml of 4°C phosphate buffered solution (PBS) and subsequently with 15 ml of 4°C 2% paraformaldehyde (PFA). Matrigel implants were removed and placed in 2% PFA at 4°C for 24 h and in X-gal solution (5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 .3H 2 O, 0.01% sodium deoxycholate, 2 mM MgCl 2 , 1 mM EGTA, and 1 mg/ml X-gal in PBS with 0.02% NP40) for 16 h. Samples were then fixed with 10% formalin, embedded in paraffin and sections of 3-4 m were prepared.
For immunohistochemical staining, specimens were deparaffinized in toluene and rehydrated. Endogenous peroxidase was blocked using 3% hydrogen peroxide followed by incubation with 5% bovine serum albumin with 5% goat serum or 5% donkey serum in PBS for 30 min. Sections were placed at 37°C with primary antibodies (polyclonal goat anti-mouse CD31 at 1:100), followed by biotin-conjugated secondary antibodies (donkey antigoat IgG from Santa Cruz (Santa Cruz, CA, USA) at 1:100, or goat anti-rabbit at 1:200 from BD Pharmingen (San Diego, CA, USA)), washed and treated with avidin-peroxidase (ABC Elite kit, Vector Laboratories, Burlingame, CA, USA) for 30 min. DAB substrate (Vector Laboratories) was used for reaction development. Sections were counterstained with hematoxylin and eosin, visualized with an Olympus BX60 microscope (Melville, NY, USA), and digital images retrieved on a computer equipped with Image Pro software (Media Cybernetics, Des Moines, IA, USA).
